anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary biliary cholangitis (PBC) is a cholestatic liver disease characterized by immune-mediated injury to small bile ducts. Although PBC is an autoimmune disease, the effectiveness of conventional immunosuppressive therapy is disappointing. Nearly 40% of PBC patients do not respond to the first-line drug UDCA. Without appropriate intervention, PBC patients eventually progress to liver cirrhosis and even death. There is an urgent need to develop new therapies. The gut-liver axis emphasizes the interconnection between the gut and the liver, and evidence is increasing that gut microbiota and bile acids play an important role in the pathogenesis of cholestatic diseases. Dysbiosis of gut microbiota, imbalance of bile acids, and immune-mediated bile duct injury constitute the triad of pathophysiology in PBC. Autoimmune cholangitis has the potential to be improved through immune system modulation. Considering the failure of conventional immunotherapies and the involvement of gut microbiota and bile acids in the pathogenesis, targeting immune factors associated with them, such as bile acid receptors, microbial-derived molecules, and related specific immune cells, may offer breakthroughs. Understanding the gut microbiota-bile acid network and related immune dysfunctions in PBC provides a new perspective on therapeutic strategies. Therefore, we summarize the latest advances in research of gut microbiota and bile acids in PBC and, for the first time, explore the possibility of related immune factors as novel immunotherapy targets. This article discusses potential therapeutic approaches focusing on regulating gut microbiota, maintaining bile acid homeostasis, their interactions, and related immune factors.
An electronic device for providing guidance and a method of operating the same are disclosed. The electronic device may detect the occurrence of a guide event and may determine a guide message to display based on the guide event. The electronic device may identify at least one emotion tag associated with the instructional message and may determine a representative visual element from a candidate set of visual elements corresponding to the at least one emotion tag based on the user context information. The electronic device may include the representative visual element in the instructional message to be displayed. The emotion tags in the guide message may include a representative emotion tag and one or more associated emotion tags. The electronic device may select a visual element candidate group based on the emotional tag in the guide message, and may select a representative visual element having the strongest association with the guide message from the visual element candidate group by using the user context information.
A galactolipid material from wheat, produced by extraction of crushed wheat grains and subsequent chromatography of the extracted material, and having a content of DGDG of 51.5%, was mixed with the polar solvents, water and glycerol in order to test the swellability. The samples, prepared in glass tubes, were alternately mixed with a rod and centrifugated at room temperature until homogeneous. The samples were inspected as to physical appearance after storing for at least a week at room temperature. Results: 20% (w/w) of galactolipid material in water gave a slightly yellow, highly viscous dispersion. Small liposomes could be observed in a polarizing microscope. At higher galactolipid concentrations a stiff gel was formed. 10% (w/w) of the same lipid material in anhydrous glycerol resulted in the formation of an opaque, highly viscous gel.
This first group will be given pediatric nutrition care (PNC) in visit 0. In this group parents will receive nutritional advice about how many calories are needed, the type and form of food that can be given so that the baby can gain weight accordingly.
Peptides of formula (I): R-CH-CO-Gly-Asn-Leu-Ser-Thr-Cys-X-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe- -Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-- NH2 (I) (where R is H or free or acylated amino; X is a valine norvaline, leucine, isoleucine, morleucine or alpha-aminobutyric acid residue) and the corresp. cpds. in which >=1 of the Asn or Gln residues are replaced by Asp and Glu respectively and/or the Asp residue is replaced by Asn. and their acid-addn. salts and Zn complexes, are new and can be prepd. by standard methods from the appropriate protected amino acids, the disulphide bridge being formed by oxidn. and the terminal COOH gp. being amidated.
Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
Disability is a life-long condition that involves different care needs and includes many psychosocial problems. Having a disabled child is for all family members; creates stress. In the studies, it was found that mothers with disabled children were more stressed and their anxiety levels were higher. There are many disabled people in Turkey and researches related to the caregiver, although there is not enough research on these people. Since activity limitations, participation restrictions and social and physical barriers are different in each disability group, caregivers' influences may also be different. Comparing the quality of life of caregivers of different disability groups and guiding the family in line with the results obtained is important for public health. It is known that the mothers of children with physical disabilities have more symptoms of depression depending on the functional levels of the children. The severity of depression was also found to be higher in people with physical disabilities than other disability groups. In addition, it has been shown that there is a positive relationship between the time spent on care of the child and the level of strain of caregivers. As the time spent on care may vary in different types of disability, families' levels of distress and anxiety may also be different. This is the rehabilitation services; In addition to the physiotherapy applied to physically disabled individuals, it is thought that the social needs of caregivers should be determined and met.In the literature, there are no studies comparing the effects of disease, anxiety levels and quality of life of parents with Muscular Dystrophy (MD), Spina Bifida (SB), Cerebral Palsy (SP) and Down Syndrome (DS). This study was planned to investigate the quality of life, anxiety level, family effects and social effects of the mothers with different physical disabilities.
BACKGROUND Trimethoprim/sulfamethoxazole and levetiracetam are commonly prescribed medications in the treatment of infections and seizures, respectively. Despite their known efficacy, each has a reputation for triggering severe and sometimes life-threatening cutaneous adverse drug reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Although the mechanism of such cutaneous adverse drug reactions cannot be fully explained, it is thought to be a type IV T cell and NK cells-mediated hypersensitivity reaction that leads to keratinocyte apoptosis and epidermal necrosis. It is also thought that cutaneous adverse drug reactions are also linked to a patient's genetic predispositions, especially the human leukocyte antigens profiles and the N-acetyl transferase 2 phenotypic variation. CASE REPORT We describe a case of Stevens-Johnson syndrome in a severely ill 51-year-old man who was treated in an outside health care facility simultaneously with Trimethoprim/sulfamethoxazole and levetiracetam. The patient presented to our Emergency Department with Stevens-Johnson syndrome believed to possibly be related to the combination of these 2 agents. CONCLUSIONS The concomitant use of Trimethoprim/sulfamethoxazole and levetiracetam might have been responsible for heightening the potential of these 2 medications to trigger an unfortunate adverse drug reaction, but no formal culprit was able to be identified and no in vivo study was performed, due to ethical considerations. Thus, through this case report we strive to increase awareness of the potential risk of simultaneously prescribing these 2 medications.
There is not a consensus definition of immunologic nonresponder individuals. In this study, we described patients whose cluster of differentiation 4（CD4)+ T-cell count remained below 200 cells/ul after 2 years of effective antiviral as immunologic nonresponders, in which viroimmunological dissociation implies a greater risk of AIDS related and non-AIDS-related illnesses. Immune-based therapy such as interleukin (IL)-2 and IL-7 have been shown to increase CD4 T-cell counts but yielded no clinical benefit in a large randomized study. We have reported that umbilical cord Tissue Mesenchymal Stem Cells (UC-MSC) treatment is safe and can significantly decrease systemic immune overactivation and improve immune reconstitution in INR patients. Meanwhile, we did not find that there was a significantly transitory increase in peripheral CD4 T-cell counts within 1-2 weeks since the onset of each MSC infusion. More important, umbilical cord-MSCs were found to be with a potential to produce IL-7 and T-cell growth factor transforming growth factor (TGF)-β in vitro and in vivo and preferentially expand CD4 T-cell response in the recipients. Therefore, development of novel interventions to reduce immune overactivation/inflammation and enhance immune reconstitution in INRs is a high priority.

Granulocyte colony-stimulating factor (G-CSF)-mobilized donor peripheral blood mononuclear cells (MNCs) are a heterogeneous population of immune cells that have a potential role in immunomodulation and hemopoiesis. Here, we hypothesized that human leukocyte antigen (HLA)-mismatched MNCs transfusion can be used to comprehensively restore or boost the host holistic immune system for INR patients, to the degree similar as immune responders.

The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy (AAIT) for INR patients. 20 INR patients received i.v. transfusion one round (3 times) of 2.0-3.0\*10E8 cells/kg of MNCs as the treated group. All of them received the conventional treatment for AIDS. The CD4 T cell numbers, HIV reservoir, side effects, symptom improvement, control of opportunistic infections and will be evaluated during the 96-week follow up.
The risk of serious cardiac impairment may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of doxorubicin at the first sign of impaired function. The preferred method for assessment of cardiac function is evaluation of LVEF measured by multi-gated radionuclide angiography (MUGA) or echocardiography (ECHO). An ECG may also be done. A baseline cardiac evaluation with a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiac toxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative anthracycline doses. The technique used for assessment should be consistent through follow-up. In patients with risk factors, particularly prior anthracycline or anthracenedione use, the monitoring of cardiac function must be particularly strict and the risk-benefit of continuing treatment with doxorubicin in patients with impaired cardiac function must be carefully evaluated.

Endomyocardial biopsy is recognized as the most sensitive diagnostic tool to detect anthracycline-induced cardiomyopathy; however, this invasive examination is not practically performed on a routine basis. ECG changes such as dysrhythmias, a reduction of the QRS voltage, or a prolongation beyond normal limits of the systolic time interval may be indicative of anthracycline-induced cardiomyopathy, but ECG is not a sensitive or specific method for following anthracycline-related cardiotoxicity.

Pediatric patients are at increased risk for developing delayed cardiotoxicity following doxorubicin administration and therefore a follow-up cardiac evaluation is recommended periodically to monitor for this delayed cardiotoxicity.

In adults, a 10% decline in LVEF to below the lower limit of normal or an absolute LVEF of 45%, or a 20% decline in LVEF at any level is indicative of deterioration in cardiac function. In pediatric patients, deterioration in cardiac function during or after the completion of therapy with doxorubicin is indicated by a drop in fractional shortening (FS) by an absolute value of ≥ 10 percentile units or below 29%, and a decline in LVEF of 10 percentile units or an LVEF below 55%. In general, if test results indicate deterioration in cardiac function associated with doxorubicin, the benefit of continued therapy should be carefully evaluated against the risk of producing irreversible cardiac damage. Acute life-threatening arrhythmias have been reported to occur during or within a few hours after doxorubicin administration.
The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
Belonging to the field of Chinese medicinal preparations, the invention relates to a TGCJ sustained-release tablet and a preparation method thereof. The TGCJ sustained-release tablet is composed of, by weight, 19.8%-69.3% of TGCJ, 9.9%-59.4% of a sustained-release material and 6.0%-60.4% of a pharmaceutical adjuvant. Ultraviolet spectrophotometry determines that the content of TGCJ, in terms of gardenoside, is not less than 70% (weight), and the weight ratio of genipin-1-beta-gentiobioside to gardenoside in the TGCJ is 1-2:10. The invention also discloses the preparation method of the TGCJ sustained-release tablet. The method includes extraction of TGCJ and preparation of the TGCJ sustained-release tablet. When the TGCJ sustained-release tablet enters the human body, drugs are released slowly, the release time can be prolonged, a stable blood concentration can be maintained, and the effectiveness is high. The TGCJ sustained-release tablet can reduce the irritation of drugs to the stomach and intestine, lower the side effect of drugs, reduce drug-taking times, and improve patient medication compliance.
The invention relates to lactobacillus plantarum boosting immunological competence and a composition comprising the bacterial strain. The bacterial strain is lactobacillus plantarum with an accession number of CGMCC6326. The bacterial strain can boost body immunity. The composition is in a form of a food or medicine composition. The invention also discloses a method of screening and measuring the lactobacillus strain, and a method of boosting body immunity by increasing the visceral index regulating bodies, and nonspecific immunity and specific immunity reactions. The objective of the lactobacillus plantarum, the composition and the methods is that: daily intake of probiotic lactic acid bacteria is adopted to replace medicines to boost immunity of human bodies, and lactic acid bacteria which are free of toxic and side effects to human bodies and beneficial to health are adopted as a new choice for treating patients with hypoimmunity.
BACKGROUND: Noise-Induced Hearing Loss (NIHL) may have a significant effect on individual job performance (IJP). These effects may exert through aggression and work-related quality of life (WRQoL). Hence, the present study was conducted to investigate the modeling of the impact of NIHL on IJP by exploring the role of aggression and WRQoL.
METHODS: In 2022, a comprehensive study was carried out on 335 industrial workers in Kaveh Industrial Town, Saveh, Iran. The study encompassed a range of assessments, including a questionnaire-based survey that included the IJP questionnaire, WRQoL questionnaire, and Aggression questionnaire, as well as a pure tone audiometry test. The data gathered from these assessments were analyzed using structural equation modeling, providing a robust framework for understanding the complex relationships between variables.
RESULTS: Based on Spearman correlation test there is a negative correlation between NIHLtotal and WRQoL and IJP, with coefficients of -0.459 (P-value < 0.01) and - 0.575 (P-value < 0.01), respectively. Additionally, there is a positive correlation between NIHLtotal and aggression, with a coefficient of 0.374 (P-value < 0.05). The direct effect coefficients for the impact of NIHLtotal on WRQoL, aggression, and IJP were - 0.412, 0.453, and - 0.128, respectively. Moreover, the indirect effect coefficients of NIHLtotal on the IJP through aggression, through WRQoL, and through both aggression and WRQoL were - 0.057, -0.275, and - 0.078, respectively.
CONCLUSION: Overall, the results indicate that NIHL had a negative and positive association with WRQoL and aggression among workers, respectively. Furthermore, IJP was found to be directly and indirectly influenced by NIHL, through reduced WRQoL and aggressive behavior as negative consequences of NIHL.
Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
Inflammation in macrophages is exacerbated under hyperglycemic conditions, contributing to chronic inflammation and impaired wound healing in diabetes. This study investigates the potential of mangiferin, a natural polyphenol, to alleviate this inflammatory response by targeting a redox-sensitive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2). Mangiferin, a known Nrf2 activator, was evaluated for its ability to counteract the hyperglycemia-induced inhibition of Nrf2 and enhance antioxidant defenses. The protective effects of mangiferin on macrophages in a hyperglycemic environment were assessed by examining the expression of Nrf2, NF-κB, NLRP3, HO-1, CAT, COX-2, IL-6, and IL-10 through gene and protein expression analyses using qPCR and immunoblotting, respectively. The mangiferin-mediated nuclear translocation of Nrf2 was evidenced, leading to a robust antioxidant response in macrophages exposed to a hyperglycemic microenvironment. This activation suppressed NF-κB signaling, reducing the expression of pro-inflammatory mediators such as COX-2 and IL-6. Additionally, mangiferin decreased NLRP3 inflammasome activation and reactive oxygen species accumulation in hyperglycemia exposed macrophages. Our findings revealed that mangiferin alleviated hyperglycemia-induced reductions in AKT phosphorylation, highlighting its potential role in modulating key signaling pathways. Furthermore, mangiferin significantly enhanced the invasiveness and migration of macrophages in a hyperglycemic environment, indicating its potential to improve wound healing. In conclusion, this study suggests that mangiferin may offer a promising therapeutic approach for managing inflammation and promoting wound healing in diabetic patients by regulating Nrf2 activity in hyperglycemia-induced macrophages.
Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI based on the 2015 International Club of Ascites (ICA) diagnostic criteria \[2\] were eligible for participation.

Screening and eligibility criteria were verified upon admission to the ICU. A diagnosis of AKI was established through comparing sCr value at time of ICU admission to that recorded in the patient's file. Patients who meet all other diagnostic criteria of HRS-AKI provided by the previous definition \[2\] were enrolled in the study. Qualified patients were subjected to baseline assessments after informed consent signature. It included vital sign measurements, presence of comorbidities, height and weight, Child-Pugh score and Sequential Organ Failure Assessment (SOFA) score. Vital signs, Blood urea nitrogen, sCr, serum sodium, serum albumin, total bilirubin, and complete blood count with differential were measured at baseline and at daily basis throughout the study period. Patients were randomized in a 1:1 ratio to receive either continuous infusion of norepinephrine in an initial dose of 0.5mg/h (Maximum 3 mg/h or oral midodrine 5mg three times/day (Maximum 12.5mg three times/day) plus octreotide 100μg/6h as subcutaneous injection (Maximum 200 μg/6h). Duration of treatment was allowed to extend to a maximum of 10 days. Administration of albumin at doses of 20 to 40 gm/day was recommended, as clinically indicated, for all patients in both study arms as per current ICA guidelines.
501,496. Liver extracts. KEIL, H. L. June 29, 1938, No. 19250. [Class 81 (i)] Liver extracts are freed from impurities, in particular from small amounts of proteins, glycogen, dextrins, glucose and lipoids, by mixing a paste of the water-soluble constituents of liver with aqueous alcohol of 60-80 per cent by volume and cooling the mixture to at least -15‹ F., preferably to 20‹F., and removing the insoluble substances which separate. The alcohol used is preferably of the strength of 70 per cent by volume. The alcoholic solution is evaporated in vacuo to. a thick syrup ; this is warmed and to each 100 grams ' are added about 800 cc. absolute alcohol; the mixture is allowed to settle, the alcohol decanted off and the residue dried under vacuum to a pasty consistency.
Patients receive atezolizumab IV over 30-60 minutes on day 1, and gemcitabine IV over 30 minutes and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or magnetic resonance imaging MRI throughout the trial. Patients undergo blood specimen collection on study.
This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.
Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a "good' response in bleed event response efficacy as stated above at 48 hours or less than "moderate" for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI.